We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

CEPHEID

Develops, manufactures, and markets molecular systems and tests for institutions to perform sophisticated genetic tes... read more Featured Products: More products

Download Mobile App




Molecular Flu/RSV Test Provides Accurate Results in 30 Minutes

By Michal Siman-Tov
Posted on 22 Nov 2016
Print article
Image: The Xpert Xpress Flu/RSV test provides results within 30 minutes, twice as fast as its predecessor Xpert Flu/RSV XC (Photo courtesy of Cepheid).
Image: The Xpert Xpress Flu/RSV test provides results within 30 minutes, twice as fast as its predecessor Xpert Flu/RSV XC (Photo courtesy of Cepheid).
The new assay rapidly tests for influenza and respiratory syncytial virus (RSV) infections on the GeneXpert System and is now available in the EU and all countries recognizing the CE Mark.

Early symptoms for a wide variety of viral and bacterial respiratory infections are often clinically indistinguishable, yet treatment is different depending on cause of infection, highlighting the importance of accurate diagnostic tests. With Xpert Xpress Flu/RSV from Cepheid (Sunnyvale, CA, USA), healthcare providers can now use a single test to provide fast reference-quality results for patients suspected of influenza or RSV infection. It provides reliable diagnosis of influenza and RSV infection within 30 minutes, twice as fast as its predecessor, Xpert Flu/RSV XC, but with comparable performance characteristics (when run in Flu-only or RSV-only reporting mode, positive results can be reported in soon as 20 minutes).

The new assay features a novel design that employs multiple targets for each virus. The built-in redundancy provides very high test sensitivity, avoiding the impact of seasonal drift that has historically been a problem with molecular tests, while maintaining high specificity.

"For too long, clinicians have been asked to treat suspected cases of influenza empirically, since gold-standard RT-PCR based tests took too long to process in the critical first 24 hours of symptom onset," said David H. Persing, MD, PhD, chief medical & technology officer, Cepheid, "With the arrival of fast molecular tests like Xpert Xpress Flu/RSV, patients and their healthcare providers can now expect an accurate diagnosis and access to targeted therapies substantially more quickly. Unnecessary treatment with antimicrobial agents can also be avoided. This supports clinical efforts to improve the patient experience, and further streamlines workflow in the laboratory, which can be particularly challenging in the midst of a busy respiratory virus season."

The GeneXpert System uses proprietary Xpert test cartridges. It provides the ability to perform from 1 to 80 Xpert tests simultaneously, and so can meet the throughput requirements from lower volume point-of-care settings to higher volume reference laboratories.

Related Links:
Cepheid


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: The utilization of liquid biopsies in cancer research is a rapidly developing field (Photo courtesy of Lightspring/Shutterstock)

Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis

B-cell lymphoma is the predominant form of cancer affecting the lymphatic system, with about 30% of patients with aggressive forms of this disease experiencing relapse. Currently, the disease’s risk assessment... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: The Sampler device could revolutionize sample collection for diagnostic tests (Photo courtesy of ReadyGo Diagnostics)

First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests

The COVID pandemic has dramatically reshaped the perception of diagnostics. Post the pandemic, a groundbreaking device that combines sample collection and processing into a single, easy-to-use disposable... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.